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Abstract
Background: Although no report has demonstrated the efficacy of corticosteroid therapy for autoimmune
pulmonary alveolar proteinosis (aPAP), we sometimes encounter patients who have received this therapy for
various reasons. However, as corticosteroids can suppress alveolar macrophage function, corticosteroid therapy
might worsen disease severity and increase the risk of infections.
Methods: For this retrospective cohort study, we sent a screening form to 165 institutions asking for information
on aPAP patients treated with corticosteroids. Of the resulting 45 patients screened, 31 were enrolled in this study.
We collected demographic data and information about corticosteroid treatment period, dose, disease severity score
(DSS) over the treatment period, and complications.
Results: DSS deteriorated during corticosteroid therapy in 23 cases (74.1 %) and the estimated overall cumulative
worsening rate was 80.8 % for the total observation period. The worsening rate was significantly higher in patients treated
with high-dose prednisolone (>18.9 mg/day, n = 16) than treated with low-dose prednisolone (≤18.9 mg/day, n = 15)
divided by median daily dose (p < 0.02). Of patients with worsening, one died of disseminated aspergillosis and another
of respiratory failure. Infections newly emerged in 6 cases during corticosteroid therapy (p< 0.05). Median serum
granulocyte/macrophage colony-stimulating factor (GM-CSF) autoantibody levels were similar to previously reported data
in a large cohort study.
Conclusion: The results demonstrate that corticosteroid therapy may worsen DSS of aPAP, increasing the risk
for infections.
Background
Pulmonary alveolar proteinosis (PAP) is a rare lung
disease in which surfactant materials accumulate abnor-
mally in the terminal bronchioli and alveoli [1, 2].
According to the etiology, PAP can be classified into three
forms; hereditary, secondary, and autoimmune PAP [2].
Hereditary PAP are caused by some gene abnormality, for
example, granulocyte/macrophage colony-stimulating fac-
tor (GM-CSF) receptor α or β insufficiency, in which
neither serum GM-CSF autoantibodies nor underlying
diseases are confirmed [3–5]. Secondary PAP develops
secondary to some underlying diseases that presumably
impair surfactant clearance because of abnormal num-
bers and functions of alveolar macrophages [6]. In pa-
tients with autoimmune PAP (aPAP), comprising 90 %
of all PAP cases, GM-CSF autoantibody (GMAb) is
excessively produced [2, 7, 8]. GMAb interferes with
GM-CSF signaling in alveolar macrophages, causing
maturation arrest and dysfunction and thus impairing
surfactant catabolism [9, 10].
Currently, the standard therapy for PAP is whole-
lung lavage [11–13]. Alternatively, since the mouse
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CSF administration by injections or inhalation has
been carried out with variable success [14–18].
As corticosteroid administration has been applied to
treat a number of autoimmune diseases, it is a reason-
able assumption that corticosteroid therapy might also
be effective treatment modality for aPAP. Evidence sup-
porting this notion includes observations that low-dose
corticosteroids stabilize the cell membrane and maintain
cell survival, that moderate-dose corticosteroids sup-
press the production of immunoglobulin by B cells, and
that high-dose corticosteroids induce apoptosis of naive
B cells and thus further suppress the production of im-
munoglobulins [19–21]. On the other hand, corticoste-
roids might inhibit phagocytosis and catabolism by
alveolar macrophages by suppressing their cytokine/che-
mokine production, possibly leading to a deterioration in
aPAP disease state [22–24]. corticosteroid therapy might
also suppress the bactericidal activity of granulocytes
and macrophages, resulting in increased susceptibility to
infections [25, 26]. Furthermore, it might worsen aPAP
due to acceleration of surfactant production in alveolar
type II cells [27]. Thus, corticosteroid therapy for auto-
immune PAP has been controversial. Based on a viewpoint
that corticosteroid may suppress the production of auto-
antibody, its administration might be helpful for the treat-
ment of aPAP. In contrast, based on another viewpoint that
corticosteroid may suppress the alveolar macrophage
functions, its administration might be harmful [28, 29]. To
settle this controversy, we investigated retrospectively the
prognosis of patients with autoimmune PAP who had been
treated with corticosteroids.
Methods
Subject and study design
For the first screening, we sent a screening form to 165
major pulmonary centers in Japan since November 21th
2013 to November 20th 2014, inquiring about their
experience with corticosteroid-administrated aPAP cases
(Fig. 1). The screening form was sent mainly by e-mail
and partially by mail. We sent additional investigation by
e-mail when the answers were inadequate. We also used
telephone if needed. Cases that met the following criteria
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Fig. 1 Profile of study cohort. aPAP: autoimmune pulmonary alveolar proteinosis
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were enrolled in this study: 1) with a definite diagnosis
of aPAP, 2) treated with corticosteroid therapy for more
than one month, and 3) without complication by other
autoimmune diseases. Diagnosis of aPAP was based on
cytological analysis of BALF or pulmonary histopatho-
logical findings, with both HRCT appearance and posi-
tive serum GMAb levels (≥1.0 μg/mL) [30, 31]. In total,
128 centers (78 %) responded to the screening, with 33
centers having experienced a total of 43 aPAP cases
that were treated with corticosteroid therapy. To these
centers, we sent a secondary investigation on patient
details to the treating physicians and we received answers
on 41 cases from 32 centers. Seven cases from 7 centers
were excluded for complications by other autoimmune
diseases and 3 cases for being treated with corticosteroid
therapy for less than one month.
The following information was collected in the second-
ary investigation: age, gender, date of diagnosis, symptoms,
present illness, past history, complicating diseases, smok-
ing status, and history of dust exposure. Also requested
was information on corticosteroid therapy, i.e., treatment
duration, corticosteroid type, dosage, recorded reason for
prescribing corticosteroid therapy, and presence of other
accompanying therapies. In addition, we also collected
data on disease severity score (DSS), and serum Krebs von
den Lungen-6 (KL-6) levels at just before and various pe-
riods during corticosteroid therapy, and 6 and 12 months
after the discontinuation of corticosteroid therapy.
The Institutional Review Board of Niigata University ap-
proved this study (approval no. 1792) and all pulmonary
physicians agreed to collaborate with us. Data of patients
were anonymously handled in a linkable manner. We ob-
tained written informed consent from the represented
case of shown in Fig. 2. The study protocol was designed
according to The Ethical Guidelines 2008 for Clinical
Studies by the Japanese Ministry of Health, Labour, and
Welfare.
Disease severity scoring
As the primary endpoint of this study, DSS was deter-
mined from the data obtained by investigation based on
the following definition, and was entered into a database
at each time point for every subject. DSS at the start of
corticosteroid therapy and various time points were
determined as described previously [8]. Briefly, DSS was
determined based on the presence of symptoms and de-
gree of reduction in PaO2 under room air in the supine
position. The categories included: DSS 1 = no symptoms
and PaO2 ≥ 70 mmHg; DSS 2 = symptomatic and PaO2 ≥
70 mmHg; DSS 3 = 60 mmHg ≤ PaO2 < 70 mmHg; DSS
4 = 50 mmHg ≤ PaO2 < 60 mmHg; and DSS 5 = PaO2 <
50 mmHg. Qualifying symptoms included dyspnea or
cough related to PAP. In subjects for whom PaO2 was
unavailable, oxygen saturation was used to estimate the
PaO2 as follows: oxygen saturation values of 94 %, 90 %,
and 85 % were used as the values representing PaO2 cut-
off values of 70, 60, and 50 mmHg, respectively.
As the percent diffusing capacity of the lung for car-
bon monoxide (%DLco), which is known to be a disease
marker of PAP, had linear correlation with DSS through
Fig. 2 A typical clinical course of a case of autoimmune pulmonary alveolar proteinosis treated with corticosteroid administration. The upper
column indicates schematic dose of the administered prednisolone (PSL) and antifungal agents each day. The middle column indicates the time
course of chest HRCT appearance (Days after the first visit were shown by arrays). The lower column indicates serum levels of Krebs von den
Lungen-6 (KL-6), surfactant protein D (SP-D), β-D glucan, Aspergillus antigen (Asper. ag.) and granulocyte/macrophage colony-stimulating factor
autoantibody (GMAb). MCFG: Micafungin; VRCZ: Voriconazole; AMPH: amphotericin B; ITCZ: Itraconazole
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DSS of 1 to 5, we considered that any increase in DSS
reflected the progression of disease [8]. Therefore, in this
study, we defined “worsening” as any increase in the
DSS.
Measurement of GM-CSF autoantibodies
The GM-CSF autoantibody concentrations in the serum
were measured using direct ELISA as described previ-
ously [30, 31].
Statistical analysis
Differences between two groups were compared using
the Wilcoxon’s rank-sum test for the continuous vari-
ables, and differences in proportions were evaluated
using Chi-squared test or Fisher’s exact test. Differences
in paired-proportions for frequencies of pulmonary in-
fections before and after corticosteroid therapy were
compared using McNemar’s test. Relationships between
DSS and other parameters were analyzed using Spear-
man’s rank-order correlation. Over all cumulative worsen-
ing rate from the date at beginning of corticosteroid
therapy until the date of worsening of DSS was estimated
according to the Kaplan-Meier method. The Kaplan-
Meier method is calculated by multiplying the probabil-
ity of the worsening event time with the probabilities of
worsening all the previous event times. A log-rank test
was used to compare the difference in the cumulative
probabilities between two groups. Variables that achieved
statistical significance in the log-rank test were subse-
quently included in a multivariate analysis using a step-
wise Cox regression procedure. P < 0.05 was considered to
be statistically significant (two-sided). Analyses were per-
formed using JMP 10.0 (SAS Institute Inc., Cary, NC,
USA) and R-version 3.1.2 (R Foundation for Statistical
Computing, Vienna, Austria).
Results
A representative case report
First, we report a typical case that received corticosteroid
therapy for 216 days (Fig. 2). A 48-year-old male who had
occasional dry cough was found to have an abnormality in
chest X-ray during a medical health check and was di-
rected to visit a hospital for intensive examination. HRCT
appearance demonstrated multifocal faint ground-glass
opacities (GGO). Due to the HRCT appearance and serum
KL-6 levels that had been elevated for 2 months, the phys-
ician decided to start 30 mg of prednisolone (PSL) orally
without pathological/cytological examination of the lung.
After 4 months, HRCT appearance worsened and serum
KL-6 levels were further elevated. The patient then under-
went bolus methylprednisolone administration (mPSL;
1000 mg/day) for 3 days, followed by oral PSL medication
tapering from 80 to 20 mg over 40 days. During the next
9 months, bolus mPSL administration was repeated twice
without improvement in GGO, followed by emergence
of consolidation in the lower left lung on HRCT with
elevation of serum β-D glucan levels and Aspergillus
antigen titer. GGO findings on HRCT and high serum
KL-6 levels let the physician to suspect PAP, a diagnosis
that was later confirmed by positive GM-CSF antibody
in serum and characteristic BAL fluid appearance.
Corticosteroid therapy was discontinued and adminis-
tration of anti-fungal antibiotics was initiated. The con-
solidation on HRCT improved, with an accompanying
reduction in β-D glucan and Aspergillus antigen levels
in the serum. Importantly, GGO on HRCT remarkably
improved within 3 months after discontinuation of cor-
ticosteroid therapy.
Retrospective cohort
Demographic and clinical findings for study subjects
Demographic data of 31 study subjects obtained at the
start of corticosteroid therapy since 2003 to 2014 and at
the diagnosis of PAP are shown in Table 1. In 29 cases,
corticosteroid therapy preceded the diagnosis of aPAP,
with a median duration of 200 days and ranging from 28
to 1,486 days. In 2 cases, corticosteroid therapy was
started at 630 days and 3,650 days after the diagnosis of
aPAP. The male/female ratio and the median age at
diagnosis were somewhat different from those of the
large cohort study in 2008 by Inoue et al., whereas the
data concerning smoking status and history of dust
exposure were similar [8]. At the initiation of cortico-
steroid therapy, 11, 7, 5, and 1 cases were complicated
by hypertension, hyperlipidemia, diabetes mellitus, pul-
monary fibrosis, and pneumonia, respectively.
Reasons for corticosteroid therapy
Subjects received corticosteroid therapy for a number
of reasons; in 28 cases because the diagnosis suspected
initially was other interstitial lung diseases (ILDs), in 2
cases because diagnosis was aPAP complicated by lung
fibrosis, and in 1 case, the initial diagnosis was an asth-
matic syndrome. Of the 28 cases that were initially diag-
nosed as other interstitial lung diseases, the diagnoses
were IIPs, drug-induced ILD, chronic hypersensitive pneu-
monitis, chronic eosinophilic pneumonia, and alveolar cell
carcinoma in 21, 4, 1, 1, and 1 cases, respectively. In all of
these cases, the corticosteroid treatment was tapered and
discontinued soon after the diagnosis of aPAP.
Dosage and duration of corticosteroid therapy
In all subjects, the cumulative dose of PSL was 400 to
17,780 mg, with a median of 2,750 mg, while the duration
ranged 28 to 1,486 days with a median of 191 days (Fig. 3a);
21 cases continued PSL medication for over 90 days. The
distribution for the average dose of PSL per day is shown in
Fig. 3b. The median daily dose was 18.9 mg/day. When we
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divided the total cohort into upper and lower halves
according to the median PSL value, 16 patients were
assigned to the high-dose group, while 15 patients were
allocated to the low-dose group. There was no difference
in the median age, gender, DSS, smoking history, history
of dust exposure, and symptoms before the start of cor-
ticosteroid therapy or duration of corticosteroid adminis-
tration between the two groups (Table 2), demonstrating
that the dichotomous process using the median daily dose
showed no confounding factor between two groups.
Of all 11 cases underwent bolus mPSL (500–1000 mg)
administration for 3 days followed by PSL (10–80 mg)
for 3 to 24 days. Five repeated the cycles.
Clinical course of aPAP during corticosteroid therapy
DSS worsened during corticosteroid therapy in 23 cases
(74.1 %, Fig. 4a) within 24 (Additional file 1) months and
the overall cumulative worsening rate was estimated to be
80.8 % over the observation period, with worsening sig-
nificantly higher in patients medicated with high-dose
corticosteroids than in those with low doses (p < 0.02,
Table 1 Demographic data for the present and literature cases








Subjects n (range) 31 29 # 223
Age, median yrs 66 (9-82) 64 (9-82) 50 (9-89)
Gender n (%)
Males 17 (55) 16 (55) 151 (68)
Females 14 (45) 13 (45) 72 (32)
Clinical symptoms n (%)
Asymptomatic 9 (29) 5 (17) 70 (32)
Symptomatic 22 (71) 24 (83) 150 (68)
Dyspnea 12 (39) 21 (72) 119 (79)
Cough 14 (45) 12 (41) 51 (34)
Sputum 1 (3) 1 (3) 8 (5)
Other 4 (13) 4 (14) 9 (6)
Smoking habits n (%)
Never-smoker 16 (52) 15 (52) 93 (43)
Current or
ex-smoker
15 (48) 14 (48) 124 (57)
Dust exposure n (%)
Yes 8 (26) 7 (24) 52 (26)
No 23 (74) 22 (76) 147 (74)
Complications n (%)
None 5 (16) 5 (17) 137 (65)
Hypertension 11 (35) 11 (38) 18 (9)
Infection 0 (0) 5 (17) 12 (6)
Hyperlipidemia 7 (22) 7 (24) 9 (4)
Diabetes mellitus 5 (16) 8 (28) 8 (4)
Autoimmune
disorders
0 (0) 0 (0) 3 (1)
Pulmonary fibrosis 2 (6) 1 (3) 3 (1)
*Inoue et al. [8]
#Two cases were excluded from enrolled 31 cases, because steroid therapy
were started after diagnosis
Fig. 3 a Duration of corticosteroid administration in each case. b A
histogram for the number of cases that underwent various doses of
corticosteroid administration
Table 2 Difference of background factors or duration of
corticosteroid administration between patients received low
and high dose corticosteroids
Factors Statistical methods P-values
Age Mann-Whitney U test 0.737
Gender χ2 test 0.200
Disease severity score χ2 test 0.266
Smoking history χ2 test 0.594
Dust exposure history χ2 test 0.916
Dyspnea χ2 test 0.886
Cough χ2 test 0.870
Duration Mann-Whitney U test 0.114
Background data were collected before the start of corticosteroid therapy.
Duration was the serial days of corticosteroid administration. “High” and “low”
dose of corticosteroids were described as Dosage and duration of corticosteroid
therapy in results
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Fig. 4 a Cumulative rate of worsening estimated using the Kaplan-Meier method. b Comparison of the cumulative worsening rate between the
high-dose (full-line) and low-dose group (dotted-line). c Duration of corticosteroid administration (bar) and antibiotic administration (whisker)
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Fig. 4b). Of those with worsened DSS, 2 died at 39 and
71 days after the start of corticosteroid therapy due to
respiratory failure and disseminated aspergillosis, re-
spectively. In 6 patients, infections newly emerged after
corticosteroid therapy (p < 0.05), including 3 cases of as-
pergillosis, and 1 case each of nocardiosis, pneumococcal
pneumonia, bacterial lung abscess of unknown pathogen,
and sepsis of Pneumococcal pneumoniae was recorded
during corticosteroid therapy, whereas one had before
corticosteroid therapy. In 6 of 7 cases, antibiotic adminis-
tration lasted before the end of corticosteroid therapy
(Fig. 4c). It is noteworthy that in 5 cases, DSS improved
after the discontinuation of corticosteroid therapy and
successful treatment of the infection. In 16 patients with
high dose corticosteroid, two patients complicated pul-
monary infections during the disease process, of which no
patient showed increased DSS after the events of infection.
In while, 15 patients with low dose corticosteroid, 4
patients complicated pulmonary infections, of which one
patient accompanied increased DSS. On the other hand,
in 25 patients after corticosteroids withdrawal, one patient
was complicated with pulmonary infections, but none
accompanied increase in DSS. As a whole, we consider
that increase in DSS is not due to pulmonary infections
but mainly due to exacerbation of PAP per se.
Consistent with the change in DSS, the number of
cases with dyspnea on exertion increased from 5 to 12
cases within the first 3 months of corticosteroid therapy,
whereas the number of cases with coughing decreased
from 6 to 5 cases. The median serum KL-6 increased
from 5033 IU/mL to 7990 IU/mL in 19 cases tested in
the initial 3 months (p < 0.05).
Prognosis after discontinuation of corticosteroid therapy
Of the 27 cases that discontinued corticosteroid therapy
after the diagnosis of aPAP, 2 could not be followed-up
due to death. Of the other 25 cases, DSS improved in 20
of 25 and 20 of 23 cases in the 6- and 12-month follow-
up surveys, respectively. Other 5 and 3 cases in the 6-
and 12-month did not change in DSS. Of these 25 cases,
11 cases did not undergo therapeutic intervention but 7
of them improved within 6 months. These results sug-
gest that the deterioration in DSS could be reversible by
the discontinuation of corticosteroid therapy.
GMAb levels after corticosteroid therapy
In all 29 cases in which the start of corticosteroid
therapy preceded the recognition of aPAP, the serum
GMAb levels were measured at aPAP diagnosis. The
median level was 10.68 (1.04–111.26) μg/mL, similar
to the levels reported in the 2008 large cohort study
by Inoue et al., suggesting that corticosteroid therapy
did not change the autoantibody levels [8]. There was
no correlation between autoantibody levels and DSS.
Discussion
This study demonstrates that corticosteroid therapy
might worsen the severity of aPAP and increase the risk
for infections. Most cases studied had been treated with
corticosteroid therapy for lung diseases other than
aPAP such as IIPs, and it was discontinued after the
diagnosis of aPAP. Considering that some patients with
diffuse GGO on HRCT were still administered cortico-
steroids for the treatment of putative IIPs without con-
firmation by pathological evaluation, we believed that the
importance of reporting the outcome of corticosteroid
therapy in patients with aPAP outweighed the analytical
limitations due to methodological difficulties in data col-
lection. Moreover, although our PAP research group has
promoted the use of new nomenclature—“autoimmune
PAP” instead of “idiopathic PAP”—since 2008, we are con-
cerned that this new nomenclature might lead pulmonary
physicians to choose corticosteroid therapy when it is ac-
tually not the ideal treatment strategy [8].
Historically, corticosteroids have been used for the
treatment of PAP, regardless of whether it is aPAP or
secondary PAP [32, 33]. Besides, side effects of cor-
ticosteroid was cautioned in a case of hereditary PAP
with homozygous stop mutation p. Ser25X of the
GMCSF receptor alpha chain [34]. Thus, corticoster-
oid therapy may exacerbate the alveolar macrophage
dysfunction in the above cases. For secondary PAP
complicated by myelodysplastic syndrome, we recently
reported that use of corticosteroid therapy signifi-
cantly worsens the survival rate of patients after the
diagnosis of PAP [35]. To our knowledge, however,
there have been no reports statistically analyzing the
outcome of aPAP patients who had been treated with
corticosteroid therapy.
As we have a database of large cross sectional study
[8], we first tried to set a control group. However, the
background factors were so multiple and complicated
such as gender, age, duration of observation periods,
smoking status, history of dust exposure, history of
treatment, and disease activity. Therefore, we realized
that it was not so easy to set the control group without
selection bias. As often noted by other retrospective
studies, researchers must take due care to avoid selec-
tion bias of study subjects. Therefore, in this study, as
we did not set a control cohort, we compared the
worsening rate of the low- and high-dose corticoster-
oid groups to examine the effect of corticosteroid
therapy on the DSS of patients with aPAP. The worsening
rate was higher in the latter group than that in the former.
Furthermore, we confirmed that there were no confound-
ing factors associated with the background of these two
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groups. Thus, we concluded that corticosteroid therapy
worsened the DSS in aPAP in a dose-dependent manner.
Considering that the disease severity increased in
most cases within one year of the start of corticosteroid
therapy, dysfunction of the alveolar macrophages pro-
gressed in the administrated patients. Although GMAb
is the causative agent for aPAP, corticosteroids should
be prescribed carefully if for the purpose of reducing
the antibody levels, despite being frequently used in
other autoimmune diseases. For this purpose, treat-
ments that do not affect alveolar macrophage function
but target B cell function or reduction of GMAb concen-
tration, for example anti-CD20 antibody and plasmapher-
esis, would be ideal [36–38].
The frequency of infections in the present survey,
i.e., 7 of 31 cases (22.6 %), was higher than expected,
particularly in comparison to our previous cohort
study (12 of 212 cases, 5.2 %), although the latter data
was from a cross sectional study [8]. Some cases re-
quired several months to eliminate their severe infec-
tions, and one patient even developed disseminated
aspergillosis that proved fatal. Most treating physicians
might not pay attention to the side effects of corticosteroid
therapy due to the paucity of available information con-
cerning the management of aPAP. In this respect, Punatar
et al. demonstrated in their meta-analysis that 75 cases of
acquired PAP reported between 1950 and 2010 were com-
plicated by opportunistic infections, with overall survival
being 56 % [26]. Of those, 13 cases had been treated with
long-term corticosteroid therapy.
Notably, 5 of 7 cases complicated by infections during
corticosteroid therapy improved, not only in terms of the
infection but also the aPAP itself, after the discontinuation
of corticosteroid therapy and antibiotic therapy. These
curious phenomena are consistent with our clinical ex-
periences and several previous case reports [39–41]. As
the number of infected cases were limited and we
could not exclude that corticosteroids induced im-
provement of PAP, we should be careful to interpret
these phenomena.
In this study, 28 of 31 patients were initially assumed
as other lung diseases such as IIPs, drug-induced ILD,
and corticosteroid therapy was prescribed for the treat-
ment of these diseases after clinical of radiological diag-
nosis based on HRCT without pathological diagnosis.
As the HRCT appearance of these diseases and/or clin-
ical features are sometimes indistinguishable from that
of aPAP, the present study cautions pulmonary physi-
cians about the casual use of corticosteroids in the
absence of a definitive diagnosis by lung biopsy. If cor-
ticosteroid therapy is needed to medicate in order to
control complex inflammatory diseases (e.g., rheuma-
toid arthritis), we should extensively survey for latent
infections before beginning corticosteroid therapy and
carefully monitor for overt infections after corticoster-
oid therapy initiation. Moreover, the dose should be
kept as low as possible.
Conclusions
This is the first systematic study of patients with aPAP
being treated with corticosteroids. Corticosteroid therapy
may worsen the DSS in aPAP patients, increasing the risk
of infections. We believe that this study will contribute to
improved management of aPAP.
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